The stock of Cellebrite DI Ltd (CLBT) has seen a 4.94% increase in the past week, with a 8.90% gain in the past month, and a -11.41% decrease in the past quarter. The volatility ratio for the week is 3.62%, and the volatility levels for the past 30 days are at 4.39% for CLBT.. The simple moving average for the past 20 days is 8.16% for CLBT’s stock, with a 11.95% simple moving average for the past 200 days.
Is It Worth Investing in Cellebrite DI Ltd (NASDAQ: CLBT) Right Now?
Company’s 36-month beta value is 1.47.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CLBT is 107.50M, and currently, short sellers hold a 1.19% ratio of that floaft. The average trading volume of CLBT on March 27, 2025 was 1.86M shares.
CLBT) stock’s latest price update
The stock price of Cellebrite DI Ltd (NASDAQ: CLBT) has dropped by -3.20 compared to previous close of 20.61. Despite this, the company has seen a gain of 4.94% in its stock price over the last five trading days. globenewswire.com reported 2025-03-18 that TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 18, 2025 (GLOBE NEWSWIRE) — Cellebrite (Nasdaq: CLBT), a leader in premier Digital Investigative solutions for the public and private sectors, today announced that the Company has filed its Annual Report on Form 20-F for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission (the “SEC”).
Analysts’ Opinion of CLBT
Many brokerage firms have already submitted their reports for CLBT stocks, with Needham repeating the rating for CLBT by listing it as a “Buy.” The predicted price for CLBT in the upcoming period, according to Needham is $13.50 based on the research report published on March 28, 2024 of the previous year 2024.
BofA Securities gave a rating of “Buy” to CLBT, setting the target price at $12 in the report published on February 16th of the previous year.
CLBT Trading at -5.10% from the 50-Day Moving Average
After a stumble in the market that brought CLBT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.14% of loss for the given period.
Volatility was left at 4.39%, however, over the last 30 days, the volatility rate increased by 3.62%, as shares surge +4.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.53% lower at present.
During the last 5 trading sessions, CLBT rose by +4.94%, which changed the moving average for the period of 200-days by +89.10% in comparison to the 20-day moving average, which settled at $18.44. In addition, Cellebrite DI Ltd saw -9.44% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLBT starting from LEEOR MOSHE BEN-PERETZ, who proposed sale 18,512 shares at the price of $20.36 back on Mar 25 ’25. After this action, LEEOR MOSHE BEN-PERETZ now owns shares of Cellebrite DI Ltd, valued at $376,996 using the latest closing price.
LEEOR MOSHE BEN-PERETZ, the Officer of Cellebrite DI Ltd, proposed sale 15,680 shares at $18.94 during a trade that took place back on Mar 19 ’25, which means that LEEOR MOSHE BEN-PERETZ is holding shares at $296,920 based on the most recent closing price.
Stock Fundamentals for CLBT
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.84 for the gross margin
The net margin for Cellebrite DI Ltd stands at -0.71. The total capital return value is set at 0.14. Equity return is now at value -152.88, with -45.76 for asset returns.
Based on Cellebrite DI Ltd (CLBT), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at 11.56. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 0.17.
Currently, EBITDA for the company is 67.51 million with net debt to EBITDA at -2.68. When we switch over and look at the enterprise to sales, we see a ratio of 11.46. The receivables turnover for the company is 4.87for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.90.
Conclusion
In a nutshell, Cellebrite DI Ltd (CLBT) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
